Clicky

Midatech Pharma Plc(MTPH)

Description: Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company's segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms. The Commercial segment distributes and sells the commercial products. Its products include Zuplenz, Gelclair, Oravig and Soltamox. Zuplenz is an oral soluble film indicated for moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Gelclair is a product indicated for the management and relief of pain due to oral mucositis. Oravig is an orally dissolving buccal tablet approved for oral thrush. Soltamox is an oral liquid solution of tamoxifen citrate for the prevention of breast cancer.


Keywords: Medicine Cancer Pharmaceutical Biopharmaceutical Clinical Medicine Pain Pipe Oncology Breast Cancer Chemotherapy Radio Antineoplastic Drugs Earl Radiotherapy Antiemetics Nanomedicine Oral Mucositis Mucositis Gelclair Post Operative Nausea

Home Page: www.midatechpharma.com

MTPH Technical Analysis

1 Caspian Point
Cardiff, CF10 4DQ
United Kingdom
Phone: 44 29 2048 0180


Officers

Name Title
Mr. Stephen A. Stamp CEO, CFO, Company Sec. & Director
Dr. Dmitry Zamoryakhin M.D. Chief Scientific Officer
Dr. Daniel Palmer MBA, Ph.D. VP of Technology
Dr. Tim Sparey Ph.D. Chief Bus. Officer
Mr. Justin Barry BSc (Hons.), MBIOL, CBIOL, QP Head of Manufacturing
Mr. Vincent Holmes VP & Head of Clinical Operations
Mr. David Benharris Pres of Midatech Pharma US Inc
Ms. Fiona Sharp Group Financial Controller

Exchange: LSE

Country: UK : United Kingdom

Currency: Pence sterling (p)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.7494
Price-to-Sales TTM: 7.4606
IPO Date:
Fiscal Year End: December
Full Time Employees: 20
Back to stocks